Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenicriviroc for Arterial Inflammation in HIV
NCT05630885Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteritis comparing CVC Arm with Placebo Arm (2 arms). Primary endpoint: Change in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index Vessel at 24 weeks. Started May 2023; status: completed.
02
Drugs
cenicriviroc
03
Conditions
arteritis
Beyond the preview
Go deeper on NCT05630885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630885.